---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-042789"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:01:16.838603+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acrivon nets ~$130M in PIPE; shares at $8.50, pre-funded warrants for 7.1M shares

## Summary
- Gross proceeds ~$130M from 8.235M shares at $8.50/share and 7.06M pre-funded warrants at $8.499/warrant.
- Pre-funded warrants exercisable at $0.001/share, immediately exercisable, no expiration.
- Investors include RA Capital, Perceptive Advisors, Paradigm BioCapital, Surveyor Capital, Sands Capital, Acorn Bioventures.
- Proceeds to fund ACR-368 registrational trials, ACR-2316, cell cycle program, AP3 platform, AI/ML; cash runway into H2 2026.
- Closing expected April 11, 2024; Jefferies acted as sole placement agent.

## SEC filing metadata
- accession: 0000950170-24-042789
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017024042789/0000950170-24-042789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024042789/acrv-20240408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-042789
- JSON: https://secwatch.observer/filing/0000950170-24-042789.json
- Plain text: https://secwatch.observer/filing/0000950170-24-042789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.